Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Change in Accured Expenses (2023 - 2025)

Historic Change in Accured Expenses for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to $638000.0.

  • NewAmsterdam Pharma's Change in Accured Expenses rose 5870.65% to $638000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$482000.0, marking a year-over-year increase of 9258.92%. This contributed to the annual value of $1.7 million for FY2024, which is 6917.73% down from last year.
  • NewAmsterdam Pharma's Change in Accured Expenses amounted to $638000.0 in Q3 2025, which was up 5870.65% from $1.4 million recorded in Q2 2025.
  • NewAmsterdam Pharma's Change in Accured Expenses' 5-year high stood at $9.3 million during Q3 2023, with a 5-year trough of -$5.8 million in Q4 2023.
  • Over the past 3 years, NewAmsterdam Pharma's median Change in Accured Expenses value was $402000.0 (recorded in 2024), while the average stood at $389090.9.
  • The largest annual percentage gain for NewAmsterdam Pharma's Change in Accured Expenses in the last 5 years was 43099.63% (2025), contrasted with its biggest fall of 25865.31% (2025).
  • Over the past 3 years, NewAmsterdam Pharma's Change in Accured Expenses (Quarter) stood at -$5.8 million in 2023, then surged by 141.3% to $2.4 million in 2024, then crashed by 73.35% to $638000.0 in 2025.
  • Its Change in Accured Expenses stands at $638000.0 for Q3 2025, versus $1.4 million for Q2 2025 and -$5.0 million for Q1 2025.